Beam Therapeutics Inc. (BEAM)

From the record

Beam Therapeutics Inc.'s filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Beam Therapeutics Inc.'s 7 filed years say what it did: revenue went from $18 thousand in fiscal 2019 to $140 million in fiscal 2025, up 344.8% a year; it rose in 5 of 6 years; the deepest fall was 83% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Beam Therapeutics Inc. lost about 6 cents for every dollar of shareholders' money. Leverage: it owed about 16 cents per dollar of assets, and net share issuance: its share count grew 20.2% over the year (the filed statements).

From the record

Beam Therapeutics Inc.'s standing among 102 graded names in its industry family: revenue of $140 million in fiscal 2025 ranks in the top 24% by size; a net margin of -57.2% ranks in the top 32%; revenue growth of 31.9% a year over the last 3 filed years ranks in the top 25% (its annual reports).

From the record

Beam Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Evans, John M. (CEO, as filed), filing under that title since 2020-02-05, 6.8 years (top 28% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 4.3 years (bottom 26%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 41%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Beam Therapeutics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $302 million against no long-term debt tagged leaves 20.4% of its assets as net cash, bottom 39% of its family; cash from operations less capital spending is -257.7% of revenue (bottom 48%); research spending of 293.1% of revenue (top 39%) (its annual report).

From the record

Beam Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 31.9% a year over the last three filed years against 344.8% over all 7, slowing (bottom 1% of its family); the newest year grew 120.1% (top 19%); research spending grew 9.5% a year (top 35%); capital spending grew -32.7% a year (top 49%) (its annual reports). Beam Therapeutics Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Beam Therapeutics Inc.'s newest year against its own record: revenue of $140 million in fiscal 2025 came in 115.5% above the $65 million its prior three years' pace pointed to (top 19% of its family); net income of $80 million against a prior three-year average of $266 million (top 22%); a net margin of -57.2% against losses larger than its revenue before (top 33%) (its annual reports).